Intralink-Spine expands clinical trials for injectable product

Spinal device company Intralink-Spine has expanded clinical trials of its Rejuve device in Australia, according to a July 14 news release.

Advertisement

Three things to know:

1. Rejuve is an injectable device that strengthens and stabilizes the degenerated disc.

2. Performed on an outpatient basis, Rejuve can be used as an adjunct or replacement to surgeries, including discectomies, spinal fusions and spinal implants.

3. The device is intended for the treatment of degenerative disc disease, lumbar pain and associated spinal diseases.

More articles on devices:
Setting spine practices up for success post-pandemic: 5 industry insights
UAMS begins data gathering initiative with spine patients
3 spine surgeons on the move in June

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.